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Background: Since the introduction of the array-CGH technique in the diagnostic workup of mental retardation,
new recurrent copy number variations and novel microdeletion/microduplication syndromes were identified. These
findings suggest that some genomic disorders have high penetrance but a wide range of phenotypic severity.
Results: We present the clinical and molecular description of four unrelated patients affected by
neurodevelopmental disorders and overlapping 7q31.1 microdeletion/microduplication, identified by array-CGH and
involving only part of the IMMP2L gene.
Conclusion: IMMP2L encodes an inner mitochondrial membrane protease-like protein, which is required for processing
of cytochromes inside mitochondria. Numerous studies reported that this gene is implicated in behavioural disorders
such as autistic spectrum disorders, attention-deficit hyperactivity disorders, and Gilles de la Tourette syndrome. We
discuss the functions of the gene suggesting that IMMP2L may act as risk factor for neurological disease.
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The IMMP2L gene encodes the apparent human homo-
logue of yeast mitochondrial inner membrane peptidase
subunit 2 (MIM 605977). The human IMMP2L gene
encodes the IMP2 protein and spans about 860Kb of gen-
omic DNA. Yeast IMP2 is required for processing of i-
cytochrome c1 and for stable expression of IMP1, which,
in turn, is the protease required for processing of pre-
COXII (cytochrome c oxidase subunit II) and i-cytochrome
b2. Interestingly, mitochondrial proteins, including COXII,
have been found associated with the appearance of neuro-
degenerative disorders [1].
Recently, genome-wide linkage studies have identified
genomic imbalances involving IMMP2L gene in 7q31.1
that are associated with autistim spectrum disorders
(AUTS9) (MIM 611015) [2], attention deficit/hyperactiv-
ity disorder (ADHD) (MIM 143465) [3] and Gilles de la
Tourette syndrome (GTS) (MIM 137580) [4-7].* Correspondence: eli.tassano@gmail.com
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unless otherwise stated.Autism spectrum disorders (ASD) are a subset of com-
plex neurodevelopmental disorders characterized by re-
duced reciprocal social interaction, impaired ability to
communicate, and a narrow range of interests and re-
petitive behaviours. ASD is clinically heterogeneous and
is often associated with other conditions such as epilepsy
and mental retardation [8,9]. ADHD is a common and
highly heritable disorder, but specific genetic risk factors
remain elusive. GTS is a neurobehavioral disorder char-
acterized by motor and vocal tics and behavioural abnor-
malities usually appearing between 3 and 8 years of age.
Here, we present the clinical and molecular data of
four unrelated patients with overlapping 7q31.1 dele-
tions/duplication disrupting IMMP2L and we discuss
the functions of the gene in this region as well as the ef-
fects of copy number variations (CNVs) on the patients’
clinical features.Case presentation
Clinical data and array-CGH results are summarized in
Table 1.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and molecular features of the four patients with interstitial 7q31.1 copy number variations disrupting
IMMP2L gene
Patient 1 Patient 2 Patient 3 Patient 4
IMMP2L exons (n) Ex3 Ex1, Ex2, Ex3 Ex1, Ex2, Ex3 Ex6
Gain/Loss Loss Loss Loss Gain
Size 269.6 kb 152.7 kb 249.9 kb 370.7 kb
Inheritance Paternal Paternal Paternal Paternal
Sex F M M M
Age at report 14 months 5 9 17 months
Birth weight (g) 3570 2830 n.a. 3420
Birth length (cm) 50 48 n.a 48
Birth OFC (cm) 34.5 35 n.a. 31
Weight (kg) 9.5 kg (25th) 19.6 kg (75th) 40.1 Kg (97th) 9.3 (<5th)
Height (cm) 78 cm (50th) 102 cm (3rd) 136.34 (75th) 78.5 (20th),
OFC (cm) 45.5 cm (25th) 52 cm (25-50th) 46.7 (25th)
Brain/CNS malformations - - - -
Psichomotor delay - + + +
Language delay - + + +
Behaviour problems - Hetero-aggressive, hyperphagia -
Epilepsy - + + -
Hypotonic - Paratonia + +
Autism - Some autistic symptoms - -
Skull abnormalities - - - -
Skeletal - Brachydactily, flat feet Scoliosis -
Other malformations Nystagmus - - -
Other dysmorphic features Mild facial dysmorphism,
frontal bossing





saddle back nose, inverted buccal
fissure, modest micrognathia
Others Negative FRMD7 gene analysis - - Negative MID1 gene analysis
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The girl is the second child of unrelated parents. The
mother shows autoimmune arthritis and hypothyroidism
treated by levothyroxine also during pregnancy while the
father is apparently healthy. Her brother at birth pre-
sented clubfoot and sacral dermal sinus. The mother
reported a paternal aunt with breast tumour. The preg-
nancy was complicated by gestational diabetes and
hypertension appearing at the eighth month of preg-
nancy. The patient was born at term by caesarean sec-
tion. Apgar score was 9 at 1st and 10 at 5th minute, birth
weight was 3570 g, head circumference (OFC) 34,5 cm,
length 50 cm. The psychomotor development was nor-
mal until the age of 13 months. She was referred to the
Istituto G. Gaslini because of horizontal and vertical
nystagmus. Neurological evaluation confirmed the pres-
ence of nystagmus with inconstant eye contact and head
deviation. Ophthalmological investigation did not iden-
tify any alteration of visual acuity. Brain MRI was nor-
mal. Abdominal ultrasound was unremarkable.Mild facial dysmorphisms including frontal bossing,
small head circumference (45.5 cm, 10th centile), and
deep-set eyes were present.Patient 2
The proband is the only child of non-consanguineous
healthy parents. No family history of neuropsychiatric
disorders was reported. The child was born at 42 weeks
of gestation by caesarean section after an uneventful
pregnancy. At birth, weight was 2830 g, length 48 cm,
and head circumference (OFC) 35 cm. Apgar score was
10 at 1st minute.
After a normal perinatal period, his psychomotor de-
velopment was evaluated as delayed: he was able to sit
without support at 12 months and to walk at 18 months,
and he did not develop any verbal language. He showed
generalized seizures at 12 months of age that were
treated with valproic acid. Brain MRI performed at the
age of 16 months was normal.
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Giannina Gaslini. On physical examination, body weight
was 19.6 kg (75th percentile), height 102 cm (3rd percent-
ile), BMI 18,8 (97th percentile), and head circumference
52 cm (25-50th percentile).
He showed minor facial dysmorphic features, small
hands and feet, bilateral retractile testes. The estimated
bone age corresponded approximately to 4 years-of age,
with dissociation between the maturation of carpal
bones and distal brachydactily.
Neurological examination showed paratonia, motor
clumsiness, wide base gait, and flat feet. Furthermore, he
presented oro-facial dyspraxia with open mouth posture,
tongue protrusion and sialorrhea, and severe language im-
pairment with inability to use any word with meaning.
The Griffiths Mental Development Scale, administered
at 5 years of chronological age, demonstrated a global
mental age of 2 years, with impairment of language as
measured by a specific sub-scale.
Although the child demonstrated some autistic symp-
toms, as well as motor stereotypes and reduced sensitiv-
ity to pain, non-verbal communication skills such as
pointing and joint attention, the DSM-IV diagnostic cri-
teria for Autism Spectrum Diagnosis were not fulfilled.
Moreover, he showed hyperactivity and attention deficit,
hyperphagia, hetero-aggressive behaviours, and sleep dis-
orders with frequent awakenings during the night.
Non-epileptic seizures occurred and the electro-
encephalogram was normal, without epileptiform dis-
charge. Laboratory investigations showed IgA deficiency
and subclinical hypothyroidism.
Patient 3
The patient is the first male child of healthy non-
consanguineous parents born at term after a normal
pregnancy. He has a family history of epilepsy. He was
referred for developmental delay to the Istituto G.Gaslini
at the age of 9 years. His weight was 40.1 Kg (97th cen-
tile) and height 136.34 cm (75th centile). His medical his-
tory included language and developmental delay with
independent walking at 18 months, and idiopathic epi-
lepsy until 3 years of age. An IQ of 75 was identified as
borderline. He was affected by celiac disease and sub-
clinical hypothyroidism. On physical examination, he
presented scattered hypochromic spots, scoliosis, hypo-
tonia with associated mild facial dysmorphisms includ-
ing high arched palate and large central incisors.
Patient 4
A 17-month old boy was admitted to the Istituto G.
Gaslini because of dysmorphisms and neurological prob-
lems. Family history included paternal grandfather with
delayed psychomotor development which normalized at
school age, and a maternal cousin of his father withdelayed speech. He was born at term to consanguineous
parents after a pregnancy characterized by threatened
abortion at 3 months. At birth, weight was 3420 g,
length 48 cm, head circumference (OFC) 31 cm, and
Apgar score 9 at 1st and 10 at 5th minute.
In the first months of life, delay in the acquisition of
psychomotor developmental milestones became progres-
sively evident, with head control at 10 months, and
babbling at 7–8 months. At the age of 17 months, his
weight was 9.3 kg (<5th percentile), height 78.5 cm (20th
centile), head circumference 46.7 cm (25th centile), chest
circumference 47.5 cm. He showed facial dysmorphisms:
frontal bossing, hypertelorism, saddle back nose, inverted
V rima oris, and modest micrognathia. He had hypotonia
and global psychomotor development and language delay.
He was not able to sit with or without support, he had not
gained control of the trunk, and he did not pronounce
meaningful phonemes. Neurological examination was nor-
mal. Severe constipation was reported, and therefore mo-
lecular analysis of MID1 gene (MIDLINE1, MIM 300552)
for Opitz G/BBB syndrome was performed. Sequence ana-
lysis of the gene was not able to identify any mutations
and MLPA did not reveal any duplications or deletions
(the analysis of the gene was performed in another hos-
pital. Data on methods are not available).Results
Patient 1
Array-CGH analysis revealed the presence of a ~ 270 kb
deletion at 7q31.1, arr [hg19] 7 q31.1(110,879,586-111,
149,166)x1, including the exon 3 of IMMP2L gene
(Figure 1A). The deletion was inherited from her healthy
father.
Further sequence analysis of FRMD7 gene (MIM
300628) within the critical interval for X-linked congeni-
tal nystagmus (NYS1; MIM 310700) on Xq26-q27 was
normal and MLPA screening did not reveal any dele-
tions or duplications within the region.Patient 2
Karyotype analysis was normal, while array-CGH dem-
onstrated the presence of an ~ 153 kb deletion at 7q31.1,
arr [hg19] 7q31.1(111,066,736-111,201,968)x1, encom-
passing exons 1, 2, and 3 of IMMP2L gene (Figure 1B).
The deletion was inherited from his healthy father.Patient 3
He had a normal karyotype and array-CGH analysis
showed the presence of ~250 kb deletion at 7q31.1, arr
[hg19] 7q31.1(111,066,736-111,316,651)x1, encompass-
ing exons 1, 2, and 3 of IMMP2L gene (Figure 1C). The
deletion was inherited from his healthy father.
Figure 1 Results of array-CGH analysis in our cases 1, 2, 3, and 4. A) Array-CGH analysis in patient 1 shows ~ 269 kb deletion at 7q31.1
(chr7:110,879,586-111,149,166) including exon 3 of IMMP2L gene. B) Array-CGH analysis in patient 2 shows a ~ 152.7 kb deletion at 7q31.1
(chr7:111,066,736-111,201,968). The deletion encompasses exons 1, 2, and 3 of IMMP2L gene. C) Array-CGH analysis in patient 3 shows the presence of
~249.9 kb deletion at 7q31.1 (chr7:111,066,736-111,316,651) encompassing exons 1, 2, and 3 of IMMP2L gene. D) Array-CGH analysis in patient 4 shows
a ~307.7 kb duplication at 7q31.1 (chr7:110,135,083-110,505,806) including exon 6 of IMMP2L gene. E) Schematic representation of deleted regions in
patients 1, 2, and 3 and of duplicated region in patient 4.
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Array-CGH revealed the presence of a first ~171 kb dupli-
cation at 7p22.1, arr [hg19] 7p22.1(4,785,596-4,956,419)
x3, including five genes (FOXK1, AP5Z1, RADIL,
PAPOLB, MMD2) and a second ~308 kb duplication at
7q31.1, arr [hg19] 7q31.1(110,135,083-110,505,806)x3, in-
cluding exon 6 of IMMP2L gene (Figure 1D). Array-CGH
of the parents showed that the child inherited the 7p22.1
duplication from his mother and the 7q31.1 duplication
from his father.
Discussion
Thanks to the widespread use of array-CGH in the diag-
nostic workup of mental retardation (MR), new recurrentCNVs and novel microdeletion/microduplication syn-
dromes have been described. The introduction of array-
CGH led to the identification of an increasing number of
individuals carrying CNVs. These findings highlighted the
presence of a strong connection between genomic disor-
ders with high penetrance and a wide range of phenotypic
severity. The recurrent CNVs identified in multiple unre-
lated patients were often associated with a broader range
of phenotypes.
A recent AUTS1 fine-mapping study, using both family-
based and case–control association analyses, detected
SNPs within DOCK4 (dedicator of cytokinesis 4) and
IMMP2L (IMP2 inner mitochondrial membrane protease-
like) that may be indexing autism susceptibility factors [2].
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result in a hyperactive mitochondrion with an increased
production of superoxide [10] and to promote the re-
lease of pro-apoptotic proteins, thereby activating cell
death pathways [11,12].
Interestingly, COXII and other mitochondrial proteins
have been found associated with the appearance of neuro-
degenerative disorders, and stroke-like episodes [13,14],
and they have been hypothesized in neuropsychiatric dis-
orders [15]. Moreover, IMMP2L contains a neuronal
leucine-rich repeat gene (LRRN3), highly expressed in fetal
brain, nested within its large third intron. Murine and
Drosophila studies demonstrated that many members of
the LRR family play an essential role in target recognition,
axonal path finding, and cell differentiation during neur-
onal development [16,17].
IMMP2L gene has been indicated as a possible candi-
date for Gilles de la Tourette syndrome [4-7].
Here we report on three cases with microdeletions
and one with a microduplication, detected by array-
CGH encompassing a region that includes only a portion
of IMMP2L. The copy number variation size ranges
from ~150 Kb to ~370 Kb. The microdeletions identified
in patients 2 and 3 affect exclusively the first three
exons, the deletion in patient 1 affects only exon 3, and
the microduplication observed in patient 4 includes ex-
clusively exon 6. Additional 7p22.1 duplication present
in our patient 4 was inherited from his mother. To our
knowledge this duplication contains five genes, i.e.
FOXK1, AP5Z1, RADIL, PAPOLB, MMD2 that till now,
could not seems to be related with a neurologic pheno-
type. No additional CNVs were identified in the other
patients (Table 2).
Recently, Bertelsen et al. [7], through screening of a
Danish cohort comprising 188 unrelated Tourette syn-
drome patients, reported seven patients with intragenic
IMMP2L deletion suggesting it as a susceptibility factor
for Tourette syndrome. These authors reported that the
deletion frequency was significantly higher in their co-
hort compared with the background population and the
Affimetrix reference cohort.
Generally, GTS syndrome appears at 2 to 14 years of
age. None of our patients showed signs of the GTS syn-
drome, but only patients 2 and 3 were the age at whichTable 2 Summary of the microdeletions/microduplications




Patient 1 F Chr7:110.879.166_111.149.166 del 270 3
Patient 2 M Chr7:111.066.736_111.201.968 del 153 1,
Patient 3 M Chr7:111.066.736_111.316.651 del 250 1,
Patient 4 M Chr7:110.135.083_110.505.806 dup 308 6symptoms of this syndrome may occur, the other two
were much younger and could develop these symptoms
in the future.
However, it is likely that IMMP2L deletions are not fully
penetrant, as underlined by the finding of deletions/dupli-
cations in unaffected fathers (Table 1) and in control pop-
ulations reported in the Database of Genomic Variants.
Seven cases of deletions and one of duplication overlap-
ping the 7q31.1 region including only IMMP2L have been
reported in the DECIPHER database (275553, 263106,
257170, 262064, 271698, 283475, 282171, 280009, 288959)
but only three deletions and the duplication have a pheno-
type description. The patients with 7q31.1 deletion pre-
sented unspecified intellectual disability and behavioural/
psychiatric abnormalities while the one with duplication
showed abdominal situs inversus and dextrocardia.
All the patients described here showed dysmorphisms,
three presented hypotonia, psichomotor and language
delay, two had epilepsy, and three showed microcephaly.
Only one patient showed some autistic symptoms, while
two showed mild skeletal defects (Table 1).
Apparently, our patient 1 presented microcephaly,
mild facial dysmorphisms, and nystagmus. No mutations
were found in FRMD7 gene (MIM 300628) involved in
the pathogenesis of the nystagmus of the child. In our
patient 4, MID1 gene analysis, responsible of Opitz G/
BBB syndrome, was negative.
Mitochondrial dysfunction was found associated with
a range of human disorders, including neuropsychiatric
disorders [18]. Therefore, defective IMMP2L may lead
to apoptosis due to a hyperactive mitochondrion, as sug-
gested by Bertelsen et al. [7], or may be a risk factor af-
fecting myelination [19].
As perturbation of mitochondrial function has serious
consequences in neurons, mutations associated with
mitochondrial proteins are a highly likely to be associ-
ated with neurological diseases. Possible effects of the
7p22.1 duplication identified in our patient 4 remain un-
known at the moment.
Conclusions
In conclusion, our data suggest that partial deletions/du-
plications of IMMP2L gene may act as risk factors for








2, 3 Paternal Unaffected
2, 3 Paternal Unaffected
Paternal Unaffected Chr7:4.785.596_4.956.419 dup 171 Kb,
maternal duplication which includes
FOXK1, AP5Z1, RADIL, PAPOLB, MMD2
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theme that the same genomic variants, in combination
with distinct genetic backgrounds, may contribute to dif-
ferent phenotypes.
Further studies on larger case series with IMMP2L
CNVs are necessary to gain a better insight into the role
of this gene in disease pathogenesis.
Methods
Standard GTG banding was performed at a resolution of
400–550 bands on metaphase chromosomes from per-
ipheral blood lymphocytes. Molecular karyotyping was
performed on the probands and their parents using Hu-
man Genome CGH Microarray Kit G3 180 (Agilent
Technologies, Palo Alto, USA) with ~13 Kb overall me-
dian probe spacing. Labelling and hybridization were
performed following the protocols provided by the man-
ufacturers. A graphical overview was obtained using the
Agilent Genomic Workbench Lite Edition Software
6.5.0.18.
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